XML 67 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($)
$ in Millions
 3 Months Ended
Apr. 04, 2021
Mar. 29, 2020
Fair Value Disclosures [Abstract]    
Net (gains)/losses recognized during the period on equity securities [1],[2] $ (401) $ 255
Less: Net (gains)/losses recognized during the period on equity securities sold during the period (28) (19)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date [3] $ (372) $ 274
[1] Reported in Other (income)/deductions––net. See Note 4.
[2] The gains in the first quarter of 2021 include, among other things, unrealized gains of $409 million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $134 million related to our investment in Allogene.
[3] Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $87 million and upward adjustments of $61 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.